Rodin Therapeutics Appoints Experienced Biotechnology Investor Ajim Tamboli as Chief Financial Officer
Boston, Mass. – August 6, 2019 – Rodin Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for synaptopathies, today announced the appointment of veteran investment professional Ajim Tamboli as chief financial officer. Tamboli brings more than 20 years of healthcare experience to the role, including as a founding partner of Endurant Capital Management and a biotech sell-side analyst.
“Ajim’s financial acumen and his deep understanding of the drug development landscape will be a considerable asset as we advance our lead program to strengthen synaptic integrity through ongoing clinical trials and continue to build out our pipeline,” said Adam Rosenberg, Rodin’s CEO. “We’re thrilled to welcome him aboard.”
Tamboli comes to Rodin from Asymmetry Capital Management where he was focused on life sciences investing. He previously was a partner at Endurant Capital Management, which he co-founded and spun out from Columbia Management, spending a combined eight years overseeing a global portfolio of biotech and pharmaceutical companies. Earlier in his career, Tamboli led coverage of multiple biopharma companies and executed dozens of IPOs and follow-on offerings as an equity analyst at Lehman Brothers. He also worked as a biotech and healthcare analyst at Credit Suisse and Lazard Freres.
Tamboli received his M.S. in biotechnology/molecular biology and B.S. in biomedical science/entrepreneurial management from the University of Pennsylvania and is a CFA® charterholder.
“Rodin’s highly selective HDAC inhibitors represent an exciting new approach to neurologic diseases driven by synaptic dysfunction,” Tamboli said. “I’m eager to help shape Rodin’s strategic and financial planning as we further advance our programs into patient populations, and I’m looking forward to contributing to this deeply experienced and dedicated team.”
About Rodin Therapeutics
Rodin Therapeutics is discovering and developing first-in-class therapeutics for synaptopathies by applying novel chemical strategies to target specific HDAC complexes and upregulate key neuronal genes. Rodin’s targeted approach to strengthening synaptic integrity, backed by a robust translational strategy, has potential across multiple diseases, such as Alzheimer’s disease, Lewy body dementia, Huntington’s disease and frontotemporal dementia, all of which are characterized by impaired neuronal and synaptic function. For more information, visit https://rodintherapeutics.com/ and follow Rodin on Twitter @Rodintx.
Ten Bridge Communications